- Home
- ITRM vs VTVT Comparison
ITRM vs VTVT Comparison
Compare ITRM & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- VTVT
- Stock Information
- Founded
- ITRM 2015
- VTVT 2015
- Country
- ITRM Ireland
- VTVT United States
- Employees
- ITRM N/A
- VTVT N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- ITRM Health Care
- VTVT Health Care
- Exchange
- ITRM Nasdaq
- VTVT Nasdaq
- Market Cap
- ITRM 40.0M
- VTVT 47.9M
- IPO Year
- ITRM 2018
- VTVT 2015
- Fundamental
- Price
- ITRM $0.68
- VTVT $19.76
- Analyst Decision
- ITRM Strong Buy
- VTVT Strong Buy
- Analyst Count
- ITRM 2
- VTVT 2
- Target Price
- ITRM $7.00
- VTVT $35.50
- AVG Volume (30 Days)
- ITRM 749.8K
- VTVT 3.0K
- Earning Date
- ITRM 11-13-2025
- VTVT 11-11-2025
- Dividend Yield
- ITRM N/A
- VTVT N/A
- EPS Growth
- ITRM N/A
- VTVT N/A
- EPS
- ITRM N/A
- VTVT N/A
- Revenue
- ITRM N/A
- VTVT $17,000.00
- Revenue This Year
- ITRM N/A
- VTVT N/A
- Revenue Next Year
- ITRM $249.35
- VTVT N/A
- P/E Ratio
- ITRM N/A
- VTVT N/A
- Revenue Growth
- ITRM N/A
- VTVT N/A
- 52 Week Low
- ITRM $0.61
- VTVT $12.62
- 52 Week High
- ITRM $3.02
- VTVT $26.99
- Technical
- Relative Strength Index (RSI)
- ITRM 43.17
- VTVT 71.89
- Support Level
- ITRM $0.61
- VTVT $15.79
- Resistance Level
- ITRM $0.76
- VTVT $21.01
- Average True Range (ATR)
- ITRM 0.05
- VTVT 0.96
- MACD
- ITRM 0.01
- VTVT 0.32
- Stochastic Oscillator
- ITRM 49.65
- VTVT 76.02
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.